TIBSOVO® - for Acute Myeloid Leukemia
TIBSOVO® (Ivosidenib) for Acute Myeloid Leukemia (AML) with a susceptible IDH1 mutation
Patients without IDH1 mutations at diagnosis should be retested at relapse because a mutation in IDH1 may emerge during treatment and at relapse. Monitor closely for symptoms of differentiation syndrome, QTc interval prolongation, anemia and electrolyte abnormalities. Treatment continued until disease progression or unacceptable toxicity.
Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration
TIBSOVO® (Ivosidenib) PO 500 mg Daily N/A N/A N/A N/A